These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26032999)

  • 1. Profiles and clinical management of hepatitis C patients in Spain: disHCovery study.
    Buti M; Franco A; Carmona I; Sánchez-Ruano JJ; Sansó A; Berenguer M; García-Buey L; Hernández-Guerra M; Morillas RM; Ledesma F; Esteban R;
    Rev Esp Quimioter; 2015 Jun; 28(3):145-53. PubMed ID: 26032999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
    Bruno S; Bollani S; Zignego AL; Pascasio JM; Magni C; Ciancio A; Caremani M; Mangia A; Marenco S; Piovesan S; Chemello L; Babudieri S; Moretti A; Gea F; Colletta C; Perez-Alvarez R; Forns X; Larrubia JR; Arenas J; Crespo J; Calvaruso V; Ceccherini Silberstein F; Maisonneuve P; Craxì A; Calleja JL;
    J Viral Hepat; 2015 May; 22(5):469-80. PubMed ID: 25311757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Toro C; Sheldon J; García-Samaniego J; Ríos P; Soriano V
    J Infect; 2007 Feb; 54(2):173-9. PubMed ID: 16569433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
    Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
    Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients.
    Barreiro P; Labarga P; Martín-Carbonero L; Amor A; Ruiz-Sancho A; Castellares C; González-Lahoz J; Soriano V
    Antivir Ther; 2006; 11(7):869-77. PubMed ID: 17302249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain.
    Rivero-Juarez A; Gutierrez-Valencia A; Castaño M; Merino D; Neukam K; Ríos-Villegas MJ; Lopez-Ruz MA; Jiménez-Aguilar P; Marquez M; Collado A; Gomez-Vidal A; Hernandez-Quero J; Tellez F; Fernandez-Fuertes E; Rivero A; López-Cortés LF;
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2247-55. PubMed ID: 26342330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study.
    Semenova T; Nemoz B; Thibault V; Lagathu G; Duverlie G; Brochot E; Trimoulet P; Payan C; Vallet S; Henquell C; Chevaliez S; Bouvier-Alias M; Maylin S; Roque-Afonso AM; Izquierdo L; Lunel-Fabiani F; Marcellin P; Morand P; Leroy V; Larrat S
    Epidemiol Infect; 2019 Jan; 147():e234. PubMed ID: 31364570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study.
    Rosso C; Caviglia GP; Ciruolo M; Ciancio A; Younes R; Olivero A; Giordanino C; Troshina G; Abate ML; Rizzetto M; Pellicano R; Saracco GM; Bugianesi E; Smedile A
    Minerva Med; 2019 Oct; 110(5):401-409. PubMed ID: 31081312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Epidemiologic Data Regarding Hepatitis C Virus Infection in Romania.
    Manuc M; Preda CM; Popescu CP; Baicuș C; Voiosu T; Pop CS; Gheorghe L; Sporea I; Trifan A; Tanțău M; Tanțău A; Ceaușu E; Proca D; Constantinescu I; Ruta SM; Fulger LE; Diculescu M; Oproiu A
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):381-386. PubMed ID: 29253053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study).
    Aguilera A; Navarro D; Rodríguez-Frias F; Viciana I; Martínez-Sapiña AM; Rodríguez MJ; Martró E; Lozano MC; Coletta E; Cardeñoso L; Suárez A; Trigo M; Rodríguez-Granjer J; Montiel N; de la Iglesia A; Alados JC; Vegas C; Bernal S; Fernández-Cuenca F; Pena MJ; Reina G; García-Bujalance S; Echevarria MJ; Benítez L; Pérez-Castro S; Ocete D; García-Arata I; Guerrero C; Rodríguez-Iglesias M; Casas P; García F
    J Viral Hepat; 2017 Sep; 24(9):725-732. PubMed ID: 28248445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping.
    Rodriguez-Frias F; Nieto-Aponte L; Gregori J; Garcia-Cehic D; Casillas R; Tabernero D; Homs M; Blasi M; Vila M; Chen Q; Vargas V; Castells L; Viladomiu L; Genesca J; Minguez B; Augustin S; Riveiro-Barciela M; Carbonell J; Perales C; Soria ME; Asensio M; Llorens M; Ordeig L; Godoy C; Buti M; Esteban R; Pumarola T; Esteban JI; Quer J
    Clin Microbiol Infect; 2017 Oct; 23(10):775.e1-775.e6. PubMed ID: 28192235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.